Esmya® long-term indication in EU

Esmya® is approved in the European Union for long-term management of symptomatic uterine fibroids1.

  • Esmya® (Ulipristal acetate 5mg) is now indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age7.
  • The efficacy and safety of intermittent treatment with Esmya® has been confirmed in the recent PEARL III extension and PEARL IV studies 7,44.
  • Esmya® is effective for bleeding control and reduction in fibroid volume7.
  • Efficacy of Esmya® is maintained even during off-treatment periods and is well tolerated7.